In the 60 years since I began my clinical studies the evolution or invention of methods for measuring key analytes, such as glucose, insulin, glucagon, GLP-1, GIP and C-peptide have not only increased our understanding but also enormously improved our treatment of diabetes and other metabolic and endocrine disorders. Some of the advances with which I have been involved personally over that period are briefly outlined and, with some temerity, proposals made as to how they might develop in the future.
MarksVMarrackDRoseFC. Hyperinsulinism in the pathogenesis of neuroglycopenic syndromes. Proc Roy Soc Med1961:54: 747 - 49.
7.
YagerJYoungRTNon-hypoglycemia is an epidemic condition. NEJM1974:91:907-8.
8.
CryerPE. Human insulin and hypoglycemia unawarenessDiabetes Care. 1990;13:536-8.
9.
ComerJ P. Semiquantitative specific test paper for glucose in urine. Anal Chem. 1956:28:1748-50.
10.
KohnJ. A rapid method of estimating blood-glucose ranges. Lancet. 1957;273:119-21.
11.
MarksVDawsonARapid stick method for determining blood-glucose concentration. Br Med J1965:1;293-4.
12.
O’GradyMJRetterathAJKeenanDBThe Use of an Automated, Portable, Glucose Control System for Overnight Glucose Control in Adolescents and Young Adults With Type 1. Diabetes. Diabetes Care. 2012Aug8.
13.
ClemensAHChangPHMyersRW The development of Biostator, a glucose controlled insulin infusion system (GCIIS) pp 23-33 in Blood Glucose Monitoring; Methodology and Clinical Applications of Continuous in Vivo Glucose Analysis; Hormone Metabolic Research Supplement Series No 7 Editors Krise-JarresJ D, G D. Molnar ThiemeStuttgart1977.
14.
DayA, HbA1c and diagnosis of diabetes. The test has finally come of age. Ann Clin Biochem2012;49; 7-8.
15.
RabharS. An abnormal hemoglobin in red cells of diabetics. Clin Chem Acta1968:22:296-8.
16.
HanasRJohnGon behalf of the international HbA1c consensus Committee; 2010 consensus sratement on the worldwide standardization of the hemoglobin A1c measurements. Ann Clin Biochem2010;47(4):290-91.
17.
CeramiAVlassaraHBrownleeM. Glucose and aging. Scientific American1987:256: 90-96.
18.
HunterSJBoydACO’HarteFPMcKillop. Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans. Diabetes. 2003;52:492-8.
19.
McKillopAMAbdel-WahabYHMooneyMH. Secretion of glycated insulin from pancreatic beta-cells in diabetes represents a novel aspect of beta-cell dysfunction and glucose toxicity. Diabetes Metab. 2002Dec;28(6 Pt 2):3S61-9; discussion 3S108-12. Review.
20.
OliveirLMALagesAGomesRAInsulin glycation by methylglyoxal results in native-like aggregation and inhibition of fibril formation. BMC Biochemistry, 2011;12;41 (http://www.Biomedcentral.com/1471-2091/12/41).
21.
YalowRSBersonS AImmunoassay of plasma insulin in man. J Clin Invest1961:39:1157-75.
22.
ThomasAThevisM; Mass spectrometric identification of degradation products of insulin and its long acting analogues in human urine for doping control purposes. Analytical Chemistry; 2007:79: 2518-2524.
23.
SamolsEMarksV.Disappearance rate of endogenous insulin in man. Lancet. 1966: 2 700. lancet
24.
SamolsEMarksV. Insulin assays in insulinomas. Brit Med J1963:1:507
25.
McIntyreNHoldsworthCDTurnerDS. New interpretation of oral glucose tolerance. Lancet; 1964:2: 20-21.
26.
DupreJAn intestinal hormone affecting glucose disposal in man. Lancet1964:2:672-73.
27.
SamolsEMarriGMarksVPromotion of insulin secretion by glucagon. Lancet1965:1:415-16.
28.
SamolsEMarriGMarksVInterrelationship of glucagon, insulin and glucose; the insulinogenic effect of glucagon. Diabetes; 1966:15: 855-66.
29.
MarksVSamolsEGlucose homeostasis pp 111-138 in Recent Advances in Endocrinology Editor JamesV H T. ChurchillLondon1968
30.
SamolsETylerJMarriGMarksV. Stimulation of glucagon secretion by oral glucose. Lancet. 1965;2:1257-9.
31.
SamolsETylerJMegyesiCMarksVImmunochemical glucagon in human pancreas, gut and plasma. Lancet1966: 2:927-29.
32.
SamolsEStagnerJIEwartRBMarksV. The order of islet microvascular cellular perfusion is B----A----D in the perfused rat pancreas. J Clin Invest. 1988;82:350-3.
33.
TurnerDSMarksV. Enhancement of glucose stimulated insulin release by an intestinal polypeptide. Lancet1972:1:1095-97.
34.
MorganLMarksV – Unpublished observations.
35.
BrownJ C. Gastric Inhibitory Polypeptide. Springer VerlagBerlin1982
36.
DupreJRossS AWatsonDBrownJ CStimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocr Metab1973:38;826-28.
37.
TurnerD SEtheridgeLMarksVBrownJ CMuttVEffectiveness of the intestinal polypeptides, IRP,GIP, VIP and motilin in insulin release in the rat, Diabetologia: 1974:10:459-463.
38.
MarksV. GIP - The Obesity Hormone. In: Current Approaches: Obesity; Ed. JamesW P TParkerS W; Duphar Laboratories Limited, London1988
39.
RanganathL.R.PinkneyJ. The Paradoxical Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Diet and Eating Behaviour in Health and Disease in pp 241-258International handbook of Behaviour, Diet and Nutrition Editors. PreedyVRWatsonRMartinCR. Springer2011.
40.
MentisNVardarliIKotheLD; GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycaemic patients with type 2 diabetes. Diabetes2011:60:1270-76.
41.
HolstJJ. Glucagon like peptide 1: a newly discovered gastrointestinal hormoneGastroenterology. 1994;107:1848-55.
42.
GreenBDIrwinNDuffyNAGaultVAO’harteFPFlattPR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.Eur J Pharmacol. 2006;547(1-3): 192-9.
43.
IrwinNGaultVFlattPRTherapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimers disease. Expert Opin Investig Drugs2010:19:1039-1048.
44.
OyerPEChoSPetersonJDSteinerDF. Studies on human proinsulin. Isolation and amino acid sequence of the human pancreatic C-peptide. J Biol Chem. 1971:246:1375-86.
45.
WheltonMJSamolsEWilliamsHSMarksV. Factitious hypoglycemia in a diabetic: metabolic studies and diagnosis with radioactive isotopes. Metabolism1968;17:923-7
46.
MarksV. C-peptide. pp 926-929 in Wiley Encyclopedia of Molecular Medicine, Editors John Wiley and Sons. 2002.
47.
UngerRH. Glucagon and insulin: a bihormonal system. Compr Ther. 1976:2:20-6.
48.
LeeYBerglundEDWangMYFuXYuXCharronMJBurgessSCUngerRHMetabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci U S A. 2012Aug13. [Epub ahead of print].
